Sökresultat
Xospata inkluderat i högkostnadsskyddet med begränsning
…43 0355 Referenser 1. Beslut TLV, publicerat den 26 februari 2021, https://www.tlv.se/beslut/besl… 2. AE Perl, G Martinelli, JE Cortes et al. N Engl J Med 2019;381:1728–40. 3. European Public Assesment Report – gilteritinib, https://www.ema.europa.eu/en/documents/assessment-report/xospata-epar-public-assessment-report_en.pdf. 2021-03-02 4. ClinicalTrials.gov. A Study of ASP2215 Versus Salvage Chemotherapy in Patients with Relapsed or Refractory Ac…
Intensified treatment options and considerations in mHSPC
…na Bajer, Business Support Specialist, carina.bajer@bayer.com, +46 70-862 04 51 For medical questions please contact; Lena Thyrell, Sr. Medical Advisor, lena.thyrell@bayer.com, +46 76-851 53 37 Use the link below to sign up for the webinar: https://www.lyyti.in/160523 PP-NUB-SE-0167-1…
Positiva resultat med Venclyxto som kombinationsbehandling för patienter med akut myeloisk leukemi
…ment response, survival and toxicity with cytarabine and anthracyclines in patients with acute myeloid leukaemia: a systematic review protocol. Syst Rev 8, 109 (2019). 6. ClinicalTrials.gov (2019). NCT02993523: A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy. https://clinicaltrials.gov/ct2/show/NCT02993523 7. Produktre…
Lynparza rekommenderas i EU för adjuvant behandling av HER2-negativ tidig bröstcancer
…cines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca. Contacts For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here. References Tutt ANJ, et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med. 2021;384:2394-2405. International Agency for Research on Cancer. Globocan 2020 – Breast….
Rozlytrek godkändes i Europa för patienter med NTRK fusion-positiva solida tumörer samt för patienter med ROS1-positiv avancerad icke småcellig lungcancer
…holder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. References [1] F. Hoffmann-La Roche Ltd. Data on file. [2] Cocco, E, et al. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018; 15:731–747 [3] Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol…